-
Federal Circuit Lacks Jurisdiction Over Award That Doesn’t Raise Issue of Patent Law
07 Aug 2025 22:20 GMT
… a substantial issue of patent law. Acorda Therapeutics Inc. v. Alkermes … , Hughes, Stark, JJ.)
Acorda Therapeutics, the developer of Ampyra®, a … was unenforceable after the patent’s expiration. However, … without judicial interpretation of patent law. The Federal …
-
The Precedent: Federal Circuit Adds Clarity to Personal Jurisdiction and Obviousness-Type Double Patenting Analyses in Regeneron Pharms
07 Mar 2025 05:43 GMT
… and Reasoning
Regeneron Pharmaceuticals filed patent infringement suits against Samsung … found this argument unavailing, citing Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc … words, if the later patent is not patentably distinct, it should terminate …
-
Federal Circuit Patent Watch: FDA Filing Can Create Personal Jurisdiction; “Compelling” Arguments that Reverse Doctrine of Equivalents was Eliminated
05 Feb 2025 18:50 GMT
… Corporation (“Shibuya”) for patent infringement resulting in a … applying its reasoning from Acorda Therapeutics Inc. v. Mylan … IPRs concerning expired patents.
The challenged patent expired before the … rights to the patentee. Although a patentee has fewer …
-
International Arbitration: Confirmation of Awards and Functus Officio
30 Oct 2025 05:18 GMT
… not “arise under” patent law merely because the … underlying dispute involved patent issues; rather jurisdiction follows … (which bars patent royalties after a patent expires) inapplicable … . Feb. 21, 2025).
5 Acorda Therapeutics, Inc. v. Alkermes PLC, …
-
Acorda Therapeutics Announces Delisting from Nasdaq
15 Apr 2024 21:15 GMT
… “ACORQ” ticker symbol.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics Announces Nasdaq Delisting Notification
03 Apr 2024 21:42 GMT
… the “pink sheets”).
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
01 Apr 2024 22:58 GMT
… and Exchange Commission.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
11 Jan 2024 13:27 GMT
… for more information.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 21:12 GMT
… at this time.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; the ability to realize … by law.
Financial Statements
Acorda Therapeutics, Inc.
Condensed Consolidated Balance …
-
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
06 Nov 2023 13:18 GMT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … of saliva or spit.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …
About
© 1995-2025